Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus

AIDS

Volumn 21, Issue 18, 2007, Pages 2546-2549

  Lacombe, Karine ^a,b,c   Boyd, Anders ^a,c   Desvarieux, Moise ^a,b,d   Serfaty, Lawrence ^c   Bonnord, Philippe ^e   Gozlan, Joel ^c,f   Molina, Jean Michel ^g   Miailhes, Patrick ^h   Lascoux Combe, Caroline ^g   Gault, Elyanne ^i,j   Girard, Pierre Marie ^b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d Department of Medicine   (United States)

^e HÔPITAL TENON   (France)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h HÔTEL DIEU   (France)

ⁱ AVICENNE HOSPITAL   (France)

^j UNIVERSITÉ PARIS 13   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; TENOFOVIR;

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DELTA AGENT HEPATITIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SUPERINFECTION;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS D, CHRONIC; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 36348974555     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f2a94f     Document Type: Article

References (24)

1. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16:1663-1671.
2. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
3. Pol S, Wesenfelder L, Dubois F, Roingeard P, Carnot F, Driss F, et al. Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers. J Viral Hepat 1994; 1:131-137.
4. Buti M, Esteban R, Espanol M, Jardi R, Rodriguez F, Esteban R, et al. Influence of human immunodeficiency virus infection on cell-mediated immunity in chronic D hepatitis. J Infect Dis 1991; 163:1351-1353.
5. Lacombe K, Massari V, Girard P, Serfaty L, Gozlan J, Pialoux G, et al. Major role of hepatitis B genotypes in liver fibrosis in HIV-HBV co-infection. AIDS 2005; 20:419-427.
6. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24:289-293.
7. Jardi R, Rodriguez F, Buti M, Costa X, Cotrina M, Galimany R, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34:404-410.
8. Mathurin P, Thibault V, Kadidja K, Ganne N, Moussalli J, El Younsi M, et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepat 2000; 7:15-22.
9. Eyster M, Sanders J, Battegay M, Di Bisceglie A. Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. Dig Dis Sci 1995; 40:1583-1588.
10. Arribas J, Gonzalez-Garcia J, Lorenzo AM, Lorenzo A, Montero D, Ladron de Guevara C, et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS 2005; 19:1361-1365.
11. Sheng WH, Hung CC, Kao JH, Chang SY, Chen MY, Hsieh SM, et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis 2007; 44:988-995.
12. Puoti C, Stati T, Magrini A. Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels. Liver 1999; 19:104-109.
13. Cole S, Gowans E, Macnaughton T, Hall P, Burrell C. Direct evidence for cytotoxicity associated with expression of hepatitis delta virus antigen. Hepatology 1991; 13:845-851.
14. Poynard T, Mathurin P, Lai C-L, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257-265.
15. Shakil AO, Hadziyannis S, Hoofnagle JH, Di Bisceglie AM, Gerin JL, Casey JL. Geographic distribution and genetic variability of hepatitis delta virus genotype I. Virology 1997; 234:160-167.
16. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
17. Radjef N, Gordien E, Ivaniushina V, Gault E, Anaes P, Drugan T, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of african hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol 2004; 78:2537-2544.
18. Soriano V, Barreiro P, Martin-Carbonero L, Castellares C, Ruiz-Sancho A, Labarga P, et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis 2007; 195:1181-1183.
19. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Short Statement of the First European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV co-infected Patients. J Hepatol 2005; 42:615-624.
20. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848.
21. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-GarcÃa J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
22. Puoti M, Rossi S, Forleo MA, Zaltron S, Spinetti A, Putzolu V, et al. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. J Hepatol 1998; 29:45-52.
23. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126:1740-1749.
24. Canbakan B, Senturk H, Tabak F, Akdogan M, Tahan V, Mert A, et al. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hepatol 2006; 21:657-663.